Special Populations

Age, gender, and renal function exert no clinically significant effects on the pharmacokinetics or pharmacodynamics of argatroban. Patients with moderate hepatic impairment (Child-Pugh score >6), compared with healthy volunteers, have an approximate fourfold decrease in drug clearance (to 1.5mL/min/kg) and an approximate threefold increase in elimination half-life (to 152 min) (Swan and Hursting, 2000). Owing to the decreased clearance, a fourfold downward adjustment in argatroban dosage is required for individuals with moderate hepatic impairment. No adjustment in initial argatroban dosage is needed for patients with renal impairment. In patients without hepatic dysfunction undergoing PCI, the pharmacokinetic values of argatroban are similar to those reported in healthy volunteers, and argatroban clearance is unaffected by age, gender, or race (Cox et al., 2004).

0 0

Post a comment